Navigation Links
GeoVax Further Strengthens Management Team
Date:3/24/2008

lege of Management at the Georgia Institute of Technology. He is an elected fellow of the American Institute for Medical and Biological Engineering, and is a past Chairman for the Georgia Biomedical Partnership, a trade association, and is recipient of the 2004 Biomedical Industry Growth Award for the State of Georgia. Dr. McNally has a Ph.D. and MSE in Bioengineering from University of Pennsylvania and an electrical engineering degree (B.E.E.) from Villanova University.

"Through my years of association with GeoVax, I have become a strong advocate of the technology developed by Dr. Robinson. During those startup years, Don Hildebrand, provided the leadership necessary to create a strong team dedicated to the development of the vaccine and entry into clinical trials, I welcome this opportunity to join the team to oversee completion of the trials, and if successful, see worldwide distribution of this lifesaving vaccine," stated Dr. McNally.

GeoVax is moving forward toward Phase 2 Human Trials.

GeoVax has completed 2 Phase 1 human trials evaluating its HIV/AIDS vaccines with excellent results and has 3 additional human trials currently underway. Due to promising results from these 5 trials GeoVax is pushing forward with plans for critically important and larger Phase 2 human trials.

GeoVax's HIV/AIDS vaccine is believed to be only the 5th HIV/AIDS vaccine moving toward Phase 2a human trials conducted by the HVTN. It was approximately the 65th vaccine protocol evaluated in earlier stage Phase 1 trials.

"We are very pleased that our HIV/AIDS vaccine continues to demonstrate the promise of not only being safe but potentially effective at eliciting potentially protective immune responses in humans," stated Dr Harriet Robinson, Senior Vice President, Research & Development, for GeoVax.

"GeoVax AIDS vaccines have passed the significant hurdles required to move into Phase 2 trials," stated GeoVax President, Don Hildebrand. Very few HI
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
4. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
5. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
6. Monitorforhire.com Adds Mobile Phone Capability Further Speeding Access to Experienced Monitors
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
9. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
10. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
11. SAFC Hitech(TM) Plans Further Expansion Into Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 Dr. Sparano is Professor of ... at the Albert Einstein College of Medicine and Associate ... Medical Center. He is also Associate Director for ... the Einstein Breast Cancer Working Group, a multidisciplinary group ... research. He also serves as Vice Chair of the ...
(Date:5/17/2013)... German . ... eye, you can see which branch a bird is sitting ... through the telephoto lens for high-magnification images requires considerable skill. ... to study proteins, the active biomolecules of cells. , Olga ... Systems Biology, and her colleagues have now come up with ...
(Date:5/17/2013)... PARK, N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability ,     New ... insect pressures , Syngenta unveiled ... celebration today at the company’s RTP Innovation Center. The ... allows company researchers to simulate any agricultural climate and ...
(Date:5/17/2013)... International, Inc. (NASDAQ: YONG ) ("Yongye" or ... crop nutrient products in the People,s Republic ... 16, 2013, the special committee (the "Special Committee") of ... provided a letter (the "Letter") issued by Abax Global ... to Full Alliance International Limited ("Full Alliance"). The Letter, ...
Breaking Biology Technology:Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4
... Without clear leadership and more transparency in federal risk ... a happy accident, rather than a foregone conclusion, says ... Project on Emerging Nanotechnologies (PEN). This sentiment was voiced ... Science & Technology Committees hearing on the National Nanotechnology ...
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), today ... Capital Market listing requirements. On April,16, 2008, the ... that it has regained compliance with Nasdaq,Marketplace Rule ... Company,s,common stock has been equal to or in ...
... Md., April 16 The Board of Managers ... Dr. Danong Chen has,been elected as the new ... previously the President and CEO of Tanox Inc., ... Genentech in 2007.,Previously Dr. Chen was Vice-President of ...
Cached Biology Technology:Limited transparency in federal nanotech research may hamper development 2Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements 2Danong Chen appointed CEO of Theranostics Health 2
(Date:5/16/2013)... Northwestern University scientists have shown a gene involved in ... proper function of the circadian clock. , In ... found the gene, called Ataxin-2, keeps the clock responsible ... the gene, the rhythm of the fruit fly,s sleep-wake ... schedule difficult for the fly. , The discovery ...
(Date:5/16/2013)... May 16, 2013 Integrated Biometrics patented ... a custom thin film transistor camera introduces Sherlock, ... roll image in the smallest and lightest form ... Appendix F Mobile ID FAP 45, Certified scanner ... in size and weight when compared to optical ...
(Date:5/16/2013)... from Canada and around the world are meeting ... Neuroscience Meeting will showcase the latest in research ... reveal clues to understanding the disorders that affect ... and this meeting will showcase the best of ... says Sam David, President of the Canadian Association ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2
... ANAHEIM, CA: Providing healthier food choices for our ... Let,s Move campaign. And a team of researchers ... to help schools serve more fresh vegetables and salad ... Food and Brand Lab, presented the findings of the ...
... NEW YORK, April 27, 2010 The Juvenile ... with Living Cell Technologies (LCT), a New Zealand-based biotechnology ... Phase II clinical trial to study the safety and ... a treatment for type 1 diabetes with significant hypoglycemia ...
... April 27 ViroPharma Incorporated (Nasdaq: VPHM ... multi-dose Phase 2 study to evaluate the safety, and ... Cinryze™ (C1 esterase inhibitor [human)] in 24 adolescents and ... by the U.S. Food and Drug Administration in ...
Cached Biology News:JDRF partners with LCT to test encapsulated cell replacement therapy for the treatment of diabetes 2JDRF partners with LCT to test encapsulated cell replacement therapy for the treatment of diabetes 3ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 2ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 3ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 4ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 5
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... purified from egg white. The extinction coefficient , ... in 10 mM phosphate-buffered saline, pH ... sodium azide and 50% glycerol. Avidin (from egg ... is purified by molecular sieving and ...
... The Zero Blunt TOPO ... Sequencing is designed for ... of blunt-end PCR products. ... 5-minute TOPO Cloning and ...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Biology Products: